• LinkedIn
GlyTherix
  • Home
  • Company
    • Management
    • Board
    • Clinical Advisory Panel
  • Product Pipeline
  • FAQs
  • News
  • Contact Us
Select Page
High-Yield GMP-Compliant Primary Cell Bank Established for Miltuximab®

High-Yield GMP-Compliant Primary Cell Bank Established for Miltuximab®

by GlyTherix | Jul 21, 2022

Date, July 21 2022: Sydney. GlyTherix is pleased to announce the successful completion of its high-yield GMP-grade stable cell line development program for its proprietary antibody Miltuximab® in partnership with international biologics manufacturer GenScript ProBio...

Recent Posts

  • GlyTherix Joins ARC Training Centre for Development of Advanced Radiochemical Technologies
  • GlyTherix & Isotopia Unite to Advance Radiopharmaceutical Innovation
  • Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement

RECENT POSTS

  • GlyTherix Joins ARC Training Centre for Development of Advanced Radiochemical Technologies
  • GlyTherix & Isotopia Unite to Advance Radiopharmaceutical Innovation
  • Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement
  • GlyTherix to Showcase its targeted radiotherapy technology at JPM Healthcare Week 2025 + Corporate Updates

ENQUIRIES

Address
Level 1, 3 Innovation Road,
Macquarie Park NSW 2113, Australia

Australian Business Number
66 621 291 996

MORE INFO

FOR SHAREHOLDERS:
Shareholder Communications Options

Would you like to talk with Glytherix about:

  • Investing in us?
  • Partnering with us?
  • Media events?
  • Some feedback?
  • Home
  • News
  • Terms of Use
  • Privacy Policy
  • Contact Us

COPYRIGHT 2025 | GLYTHERIX - ALL RIGHTS RESERVED